Similar articles for PMID: 24511050

Year	Number of Results
2000	1
2004	1
2006	4
2007	4
2008	2
2009	2
2011	3
2012	8
2013	13
2014	7
2016	4
2017	2
2018	2
2019	3
2020	2
2021	6
2022	3
2024	0

1

Treatment of collecting duct carcinoma: current status and future perspectives.

Procopio G, Testa I, Iacovelli R, Grassi P, Verzoni E, Garanzini E, Colecchia M, Torelli T, De Braud F. Procopio G, et al. Anticancer Res. 2014 Feb;34(2):1027-30. Anticancer Res. 2014. PMID: 24511050 Free article.

2

Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies.

Antoun S, Lanoy E, Iacovelli R, Albiges-Sauvin L, Loriot Y, Merad-Taoufik M, Fizazi K, di Palma M, Baracos VE, Escudier B. Antoun S, et al. Cancer. 2013 Sep 15;119(18):3377-84. doi: 10.1002/cncr.28218. Epub 2013 Jun 25. Cancer. 2013. PMID: 23801109 Free article.

3

Effects of antiangiogenic therapy.

von Falck C, Wacker F, Rosenthal H. von Falck C, et al. J Vasc Interv Radiol. 2012 Nov;23(11):1503. doi: 10.1016/j.jvir.2012.08.002. J Vasc Interv Radiol. 2012. PMID: 23101922 No abstract available.

4

[Development of angiogenesis inhibitory combination therapies for treatment of renal cell carcinoma].

Bartsch G Jr, Eggert K, Soker S, Fiedler W, Laack E, Volkmer BG, Gschwend J, Bokemeyer C, Hautmann R, Schuch G. Bartsch G Jr, et al. Urologe A. 2007 Sep;46(9):1289-90. doi: 10.1007/s00120-007-1393-7. Urologe A. 2007. PMID: 17624513 German. No abstract available.

5

Impact of anti-angiogenic treatments on metastatic renal cell carcinoma.

Ainsworth NL, Lee JS, Eisen T. Ainsworth NL, et al. Expert Rev Anticancer Ther. 2009 Dec;9(12):1793-805. doi: 10.1586/era.09.144. Expert Rev Anticancer Ther. 2009. PMID: 19954291 Review.

6

c-KIT: potential predictive factor for the efficacy of sorafenib in metastatic renal cell carcinoma with sarcomatoid feature.

Zhang HL, Zhu Y, Qin XJ, Wang CF, Yao XD, Zhang SL, Dai B, Zhu YP, Shi GH, Ye DW. Zhang HL, et al. Clin Genitourin Cancer. 2013 Jun;11(2):134-40. doi: 10.1016/j.clgc.2012.08.007. Epub 2012 Oct 9. Clin Genitourin Cancer. 2013. PMID: 23058498

7

Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.

Hittinger M, Staehler M, Schramm N, Ubleis C, Becker C, Reiser M, Berger F. Hittinger M, et al. Urol Oncol. 2012 Sep;30(5):695-703. doi: 10.1016/j.urolonc.2010.10.011. Epub 2011 Aug 24. Urol Oncol. 2012. PMID: 21865061

8

Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.

Turnbull JD, Cobert J, Jaffe T, Harrison MR, George DJ, Armstrong AJ. Turnbull JD, et al. Clin Genitourin Cancer. 2013 Mar;11(1):45-50. doi: 10.1016/j.clgc.2012.06.001. Epub 2012 Oct 4. Clin Genitourin Cancer. 2013. PMID: 23041453

9

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.

Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, Zarba JJ, Gladkov OA, Lee E, Szczylik C, McCann L, Rubin SD, Chen M, Davis ID. Sternberg CN, et al. Eur J Cancer. 2013 Apr;49(6):1287-96. doi: 10.1016/j.ejca.2012.12.010. Epub 2013 Jan 12. Eur J Cancer. 2013. PMID: 23321547 Clinical Trial.

10

Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.

Grenader T, Rosenbaum E, Zilber S, Bogot N, Shavit L. Grenader T, et al. Clin Genitourin Cancer. 2013 Jun;11(2):201-3. doi: 10.1016/j.clgc.2012.11.005. Epub 2012 Dec 23. Clin Genitourin Cancer. 2013. PMID: 23266054 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

56 results

Results by year